NCT07098117View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetic Profile of Single and Multiple Dose Escalation Topical Dermal Administration of SHR0302 Alkali Gel in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Preoperative Sedation of Adults
Interventions
DRUG

SHR0302 Base Gel

Part I: once daily. Part 2:, twice daily.

DRUG

SHR0302 Base Gel Placebo

Part I: once daily. Part II: twice daily.

Trial Locations (1)

200433

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT07098117 - A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetic Profile of Single and Multiple Dose Escalation Topical Dermal Administration of SHR0302 Alkali Gel in Healthy Subjects | Biotech Hunter | Biotech Hunter